Clinical Validation

A 200 patient clinical trial based on Barrett's surveillance for oesophageal cancer has already been completed, with excellent results. The diagnostic algorithm was able to identify healthy and benign oesophageal biopsies with 99% specificity; meaning healthy diagnoses are given with certainty. At current performance, which is expected to improve with additional data, the false-positive rate is 48%. In a population where 90% of biopsies are non-dysplastic up to 47% fewer biopsies would be sent for further analyses, representing significant time and cost savings.


To find out more please contact us.